TransMedics Q1 revenue $143.5M (+48% YoY), net income $25.7M; raises FY2025 guidance to $565-585M

TransMedics Group, Inc.

2025-Q1 EPS reported $0.70 revenue$143,537,000

Q1 revenue $143.5M (+48% YoY from $96.9M); net income $25.7M ($0.70 diluted EPS), up from $12.2M in Q1 2024.
Gross margin 61% vs 62% a year ago; operating expenses $60.8M (incl. $8.7M stock comp) vs $47.5M.
FY2025 revenue guidance raised to $565-585M (from $530-552M), representing ~30% YoY growth at midpoint.
Cash balance $310.1M as of March 31, 2025; owned 21 aircraft for organ logistics.
Announced design center and manufacturing facility in Mirandola, Italy; 10 abstracts at ISHLT meeting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.